Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
نویسندگان
چکیده
منابع مشابه
Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
OBJECTIVE To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, over 52 weeks in patients with active psoriatic arthritis (PsA) despite prior treatment. METHODS Patients were randomized to placebo (n = 168), apremilast 20 mg BID (n = 168), or apremilast 30 mg BID (n = 168). Patients whose swollen and tender joint counts had not improved by ≥ 20% at Week 16 ...
متن کاملrandomized controlled trial study about compare of post operative pain after milligan morgan versus submucosal hemorrhoidectomy with & without pudendal nerve marcaine block in patients that had hemorrhoidectomy in imam hossein hospital of shahrood in 1389-90
مقدمه:هموروئید یکی از شایعترین بیماریهای جراحی ناحیه آنورکتال است که با درد و خونریزی بروز می کند. کاهش دردبعد عمل علاوه بر افزایش رضایت بیمار باعث کاهش مدت بستری و کاهش بار تحمیلی بر روی اقتصاد جامعه می گردد. مطالعه حاضر مقایسه ای از لحاظ میزان درد و میزان تأثیر مارکائین به عنوان روشی برای پروفیلاکسی درد بعداز عمل،دو روش هموروئیدکتومی باز و بسته انجام می دهد. مواد وروشها: این مطالعه کارآزمایی...
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
OBJECTIVES Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy. METHODS In the 24-week, placebo-controlled phase of...
متن کامل52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
Objective To compare the 52-week efficacy and safety of SB4 [an etanercept biosimilar] with reference etanercept (ETN) in patients with active RA. Methods In a phase 3, randomized, double-blind, multicentre study, patients with moderate to severe RA despite MTX treatment were randomized to receive 50 mg/week of s.c. SB4 or ETN up to week 52. Efficacy assessments included ACR response rates, 2...
متن کاملMaintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
OBJECTIVE To evaluate the efficacy and safety of ustekinumab through 2 years in adult patients with active psoriatic arthritis (PsA). METHODS A total of 615 adult patients with active PsA were randomized to placebo, ustekinumab 45 mg, or ustekinumab 90 mg, at weeks 0, 4, and every 12 weeks through week 88 (last dose). At week 16, patients with <5% improvement in both tender and swollen joint ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Rheumatology
سال: 2015
ISSN: 0315-162X,1499-2752
DOI: 10.3899/jrheum.140647